EQUITY ALERT: The Rosen Law Firm Announces Investigation of Auspex Pharmaceuticals, Inc. Concerning its Proposed Sale to Teva Pharmaceuticals Industries Ltd. – ASPX

The Rosen Law Firm, P.A., a global investor rights law firm, announces that it is investigating the Board of Directors of Auspex Pharmaceuticals, Inc. (NASDAQ:ASPX) for possible breaches of fiduciary duty and other violations of law by failing to adequately shop Auspex to maximize shareholder value before agreeing to be acquired by Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA).

If you would like to join the action, go to http://rosenlegal.com/cases-564.html or contact Phillip Kim or Kevin Chan toll-free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com. There is no cost or obligation to you.

Under the terms of the proposed transaction, shareholders will receive $101 in cash for each share of Auspex common stock they own. The proposed transaction is valued at approximately $3.5 billion. The investigation relates to whether the proposal is fair to the public shareholders of Auspex and whether Auspex’s Board breached its fiduciary duties in connection with the proposed sale.

If you currently own shares of Auspex and wish to obtain additional information, please visit the website at http://rosenlegal.com/cases-564.html. You may also contact Phillip Kim or Kevin Chan of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contacts:

Phillip Kim, Esq.
Kevin Chan, Esq.
Laurence Rosen, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: 1-866-767-3653
Fax: (212) 202-3827
pkim@rosenlegal.com
kchan@rosenlegal.com
lrosen@rosenlegal.com
www.rosenlegal.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.